Gilead Sciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan Seigerman from BMO Capital maintained a Buy rating on the stock and has a $174.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evan Seigerman has given his Buy rating due to a combination of factors tied to Gilead’s expanding growth drivers and attractive valuation. He points to the planned acquisition of Tubulis as a strategically important move that deepens Gilead’s position in oncology and inflammatory diseases, while also creating synergies with the company’s existing antibody-drug conjugate portfolio.
Seigerman also highlights Tubulis’ lead program, TUB-040, which has shown encouraging efficacy and tolerability in platinum-resistant ovarian cancer and is moving toward Phase 3 trials, supporting a more durable oncology franchise beyond HIV. Combined with recent deals for Ouro and Arcellx and the ongoing momentum from key assets like Trodelvy and cell therapies, he believes Gilead is well placed for its next leg of growth, and that the stock’s discount to large-cap peers offers compelling upside as the oncology pipeline is further de-risked.
Seigerman covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Vertex Pharmaceuticals, and Eli Lilly & Co. According to TipRanks, Seigerman has an average return of 8.3% and a 52.24% success rate on recommended stocks.
In another report released today, Needham also maintained a Buy rating on the stock with a $170.00 price target.